PDCD1 and non-small cell lung carcinoma: An interim analysis of AMBER study, posted in SITC 2018 meeting [71], revealed that for patients with advanced NSCLC after resistance to PD-1/L1 antibody, 9% ORR was achieved by 100 mg TSR-022 (anti-TIM3) combined with 500 mg TSR-042 (anti-PD-1) and 15% by each 300 mg, with acceptable adverse effects (6.7% grade ≥ 3).